MET and cancer: Although several agents targeting c-MET have been examined in clinical trials but the results range from relatively high response rates to prominent failure, which clearly justify the need for more comprehensive studies to understand the role of c-MET in cancer pathogenesis and the crucial need for the discovery of new c-MET inhibitors with potential novel binding modes and cost-effectiveness.